Darolutamide (ODM-201) in the treatment of nmCRPC

Earlier this year we had reported on the initial presentation of data demonstrating the efficacy and safety of darolutamide (formerly known as ODM-201), a third “super-antiandrogen” — similar to enzalutamide (Xtandi) and apalutamide (Erleada), in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Pembrolizumab in treatment of advanced prostate cancer

We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …

Upcoming clinical trial of PSMA-linked lutetium-177 in recurrent mCRPC

According to a recent media release, a company called Endocyte has reached agreement with the US Food and Drug Administration about the design of a pivotal Phase III clinical trial that will test the effectiveness and safety of 177Lu-PSMA-617 in men with recurrent, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

At ASCO this year … “one that got away”

An abstract that we missed at the ASCO meeting this year came to our attention when we read this article by Dr. Jeffrey Kirshner: “Ten practice changes I will make after attending ASCO 2017“. … READ MORE …

Unwarranted conclusions about treatment of oligometastatic prostate cancer

Many patients wonder, if they just have a couple of metastases, why can’t those be “zapped” by a few quick SBRT treatments and they can’t thereby be cured of their prostate cancer? Or, even if they can’t be cured, can’t the cancer’s progression be slowed down? … READ MORE …

US-based, Phase II trial of lutetium-177 PSMA-directed endoradiotherapy

We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific membrane antigen 617 (177Lu-PSMA-617) for treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

The “hyping” of new forms of treatment for cancer

In a newly published article on the STAT web site, two clinicians at Oregon Health and Science University argue that the benefits of immunotherapy in the treatment of cancer are being greatly over-“hyped”. … READ MORE …